Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 2.21
XOMA's Cash to Debt is ranked higher than
62% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. XOMA: 2.21 )
XOMA' s 10-Year Cash to Debt Range
Min: 0.08   Max: 68.89
Current: 2.21

0.08
68.89
Equity to Asset 0.04
XOMA's Equity to Asset is ranked higher than
53% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. XOMA: 0.04 )
XOMA' s 10-Year Equity to Asset Range
Min: -0.6   Max: 0.66
Current: 0.04

-0.6
0.66
F-Score: 2
Z-Score: -14.96
M-Score: -3.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -433.73
XOMA's Operating margin (%) is ranked higher than
62% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. XOMA: -433.73 )
XOMA' s 10-Year Operating margin (%) Range
Min: -2191.67   Max: 13.17
Current: -433.73

-2191.67
13.17
Net-margin (%) -203.01
XOMA's Net-margin (%) is ranked higher than
66% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. XOMA: -203.01 )
XOMA' s 10-Year Net-margin (%) Range
Min: -2153.94   Max: 14.89
Current: -203.01

-2153.94
14.89
ROA (%) -38.85
XOMA's ROA (%) is ranked higher than
69% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. XOMA: -38.85 )
XOMA' s 10-Year ROA (%) Range
Min: -139.63   Max: 4.68
Current: -38.85

-139.63
4.68
ROC (Joel Greenblatt) (%) -1436.39
XOMA's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. XOMA: -1436.39 )
XOMA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1413.82   Max: 53.99
Current: -1436.39

-1413.82
53.99
Revenue Growth (3Y)(%) -55.70
XOMA's Revenue Growth (3Y)(%) is ranked higher than
59% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. XOMA: -55.70 )
XOMA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -60.9   Max: 147.7
Current: -55.7

-60.9
147.7
EBITDA Growth (3Y)(%) -29.20
XOMA's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. XOMA: -29.20 )
XOMA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -39.7   Max: 31.1
Current: -29.2

-39.7
31.1
EPS Growth (3Y)(%) -29.80
XOMA's EPS Growth (3Y)(%) is ranked higher than
62% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. XOMA: -29.80 )
XOMA' s 10-Year EPS Growth (3Y)(%) Range
Min: -53   Max: 36.5
Current: -29.8

-53
36.5
» XOMA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

XOMA Guru Trades in Q4 2013

Paul Tudor Jones 20,425 sh (New)
» More
Q1 2014

XOMA Guru Trades in Q1 2014

John Burbank 49,774 sh (New)
Louis Moore Bacon 75,000 sh (New)
Paul Tudor Jones 33,233 sh (+62.71%)
» More
Q2 2014

XOMA Guru Trades in Q2 2014

Louis Moore Bacon 75,000 sh (unchged)
Paul Tudor Jones Sold Out
John Burbank Sold Out
» More
Q3 2014

XOMA Guru Trades in Q3 2014

Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 118.40
XOMA's P/B is ranked lower than
55% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. XOMA: 118.40 )
XOMA' s 10-Year P/B Range
Min: 2.28   Max: 1428.75
Current: 118.4

2.28
1428.75
P/S 21.80
XOMA's P/S is ranked higher than
68% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. XOMA: 21.80 )
XOMA' s 10-Year P/S Range
Min: 0.55   Max: 63.23
Current: 21.8

0.55
63.23
EV-to-EBIT -4.64
XOMA's EV-to-EBIT is ranked higher than
56% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. XOMA: -4.64 )
XOMA' s 10-Year EV-to-EBIT Range
Min: -202.4   Max: 11.4
Current: -4.64

-202.4
11.4
Current Ratio 2.30
XOMA's Current Ratio is ranked higher than
63% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. XOMA: 2.30 )
XOMA' s 10-Year Current Ratio Range
Min: 1.13   Max: 6.32
Current: 2.3

1.13
6.32
Quick Ratio 2.30
XOMA's Quick Ratio is ranked higher than
64% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. XOMA: 2.30 )
XOMA' s 10-Year Quick Ratio Range
Min: 1.13   Max: 6.32
Current: 2.3

1.13
6.32
Days Sales Outstanding 57.90
XOMA's Days Sales Outstanding is ranked higher than
84% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. XOMA: 57.90 )
XOMA' s 10-Year Days Sales Outstanding Range
Min: 7.93   Max: 882.08
Current: 57.9

7.93
882.08

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 118.70
XOMA's Price/Tangible Book is ranked lower than
56% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. XOMA: 118.70 )
XOMA' s 10-Year Price/Tangible Book Range
Min: 0.77   Max: 7219
Current: 118.7

0.77
7219
Price/Median PS Value 3.80
XOMA's Price/Median PS Value is ranked higher than
67% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. XOMA: 3.80 )
XOMA' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 15.9
Current: 3.8

0.1
15.9
Earnings Yield (Greenblatt) -22.10
XOMA's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. XOMA: -22.10 )
XOMA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -22.1   Max: 21.8
Current: -22.1

-22.1
21.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:X0M.Germany,
XOMA Corp was incorporated in Delaware on 1981 and became a Bermuda-exempted company in December 1998. The Company is a biotechnology company, which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company builds a product pipeline that includes multiple proprietary and collaborative development programs. Its proprietary preclinical pipeline includes classes of antibodies that activate, sensitize, or deactivate the insulin receptor in vivo, that have been named as XMet. This portfolio of antibodies represents potential new therapeutic approaches to the treatment of diabetes and several diseases that involve insulin, which it believe may be orphan drug opportunities. Its main product candidate is XOMA 052, a potent monoclonal antibody with the potential to improve the treatment of patients with a number of diseases in which inflammation is either the cause or plays a considerable role. The company receives royalties on approved products, RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis, LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration, and the Company no longer receives royalties on sales of CIMZIA. XOMA has granted more than 60 licenses to biotechnology and pharmaceutical companies to use the Company's patented and proprietary technologies relating to bacterial expression of recombinant pharmaceutical products.
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
comment on XOMA Mar 06 2013 
XOMA Ltd. Reports Operating Results (10-K) Mar 10 2011 
XOMA Ltd. Reports Operating Results (10-K/A) Dec 27 2010 
XOMA Ltd. Reports Operating Results (10-Q/A) Nov 12 2010 
XOMA Ltd. Reports Operating Results (10-Q) May 06 2010 
XOMA Ltd. Reports Operating Results (10-Q) Aug 06 2009 
XOMA Ltd. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Servier Initiates Phase 2 Study of Gevokizumab in Patients With Diabetic Nephropathy Apr 01 2015
8:02 am XOMA announces initiation of Phase 2 study of Gevokizumab to treat patients with Diabetic... Apr 01 2015
Servier Initiates Phase 2 Study of Gevokizumab in Patients With Diabetic Nephropathy Apr 01 2015
XOMA Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2014 Financial Results Mar 25 2015
Aldeyra Initiates Phase II Sjogren-Larsson Syndrome Study - Analyst Blog Mar 19 2015
XOMA CORP Financials Mar 18 2015
XOMA Reports Narrower Y/Y Loss in Q4, Misses on Revs - Analyst Blog Mar 12 2015
XOMA CORP Files SEC form 10-K, Annual Report Mar 11 2015
XOMA Corp Earnings Call scheduled for 4:30 pm ET today Mar 11 2015
Xoma reports 4Q loss Mar 11 2015
Xoma reports 4Q loss Mar 11 2015
XOMA Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2014 Financial Results Mar 11 2015
Q4 2014 XOMA Corp Earnings Release - After Market Close Mar 11 2015
XOMA Shares Spike Higher Following Wedbush Price Target Increase Mar 09 2015
XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting Mar 07 2015
XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting Mar 07 2015
XOMA Announces Retirement of Fred Kurland and Appointment of Thomas Burns as Chief Financial Officer Mar 05 2015
XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015 Mar 05 2015
XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015 Mar 05 2015
XOMA CORP Files SEC form 8-K, Change in Directors or Principal Officers Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK